SCHEMBL14197833

SCHEMBL14197833

Cn1cc(I)c2cccnc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.49
ELANE P08246 1/20 0.47
CCNT1 O60563 1/20 0.46
PIM1 P11309 1/20 0.46
CCNA2 P20248 1/20 0.46
CDK2 P24941 1/20 0.46
CDK9 P50750 1/20 0.46
CDK5 Q00535 1/20 0.46
CDK5R1 Q15078 1/20 0.46
KDM4E B2RXH2 3/20 0.42
KDM6B O15054 1/20 0.42
KDM5A P29375 1/20 0.42
KDM4C Q9H3R0 1/20 0.42
HASPIN Q8TF76 1/20 0.41
GSK3B P49841 3/20 0.41
CDK1 P06493 3/20 0.40
CCNB1 P14635 3/20 0.40
FEN1 P39748 1/20 0.40
MET P08581 1/20 0.40
CCNB2 O95067 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL823082 0.78 DYRK1A (0.50) DYRK1ACCNT1PIM1CCNA2CDK2
SCHEMBL28108747 0.77 ELANE (0.43) DYRK1AELANEKDM4EFEN1BRD4
SCHEMBL1892910 0.77 DYRK1A (0.49) DYRK1AELANECCNT1PIM1CCNA2
SCHEMBL20674192 0.77 DYRK1A (0.49) DYRK1AELANECCNT1PIM1CCNA2
SCHEMBL16307577 0.77 DYRK1A (0.49) DYRK1AELANECCNT1PIM1CCNA2
SCHEMBL30503547 0.77 DYRK1A (0.49) DYRK1ACCNT1PIM1CCNA2CDK2
SCHEMBL30731192 0.77 DYRK1A (0.49) DYRK1AELANECCNT1PIM1CCNA2
SCHEMBL22149167 0.77 DYRK1A (0.49) DYRK1AELANECCNT1PIM1CCNA2
SCHEMBL15792325 0.77 DYRK1A (0.49) DYRK1ACCNT1PIM1CCNA2CDK2
SCHEMBL27439703 0.76 DYRK1A (0.59) DYRK1ACCNT1PIM1CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230190751-A1 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors NOVARTIS INSTITUTE FOR FUNTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2023-06-22 US disclosed
EP-3133074-B1 7-AZAINDOLE DERIVATIVES MERCK PATENT GMBH (DE) 2020-12-09 EP disclosed
EP-3133074-B1 7-AZAINDOLE DERIVATIVES MERCK PATENT GMBH (DE) 2020-12-09 EP disclosed
US-9725446-B2 7-azaindole derivatives MERCK PATENT GMBH (DE) 2017-08-08 US disclosed
US-9725446-B2 7-azaindole derivatives MERCK PATENT GMBH (DE) 2017-08-08 US disclosed
US-9725446-B2 7-azaindole derivatives MERCK PATENT GMBH (DE) 2017-08-08 US disclosed
EP-3133074-A2 7-AZAINDOLE DERIVATIVES Merck Patent GmbH (DE) 2017-02-22 EP disclosed
EP-3133074-A2 7-AZAINDOLE DERIVATIVES Merck Patent GmbH (DE) 2017-02-22 EP disclosed
EP-2670748-B1 7-AZAINDOLE DERIVATIVES MERCK PATENT GMBH (DE) 2016-09-28 EP disclosed
EP-2670748-B1 7-AZAINDOLE DERIVATIVES MERCK PATENT GMBH (DE) 2016-09-28 EP disclosed
US-20150152104-A1 7-AZAINDOLE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-04 US disclosed
US-20150152104-A1 7-AZAINDOLE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-04 US disclosed
US-8981101-B2 7-azaindole derivatives MERCK PATENT GMBH (DE) 2015-03-17 US disclosed
US-8981101-B2 7-azaindole derivatives MERCK PATENT GMBH (DE) 2015-03-17 US disclosed
US-8981101-B2 7-azaindole derivatives MERCK PATENT GMBH (DE) 2015-03-17 US disclosed
EP-2746281-A2 7-azaindole derivatives Merck Patent GmbH (DE) 2014-06-25 EP disclosed
EP-2746281-A2 7-azaindole derivatives Merck Patent GmbH (DE) 2014-06-25 EP disclosed
US-20130310391-A1 7-AZAINDOLE DERIVATIVES MERCK PATENT GMBH (DE) 2013-11-21 US disclosed
US-20130310391-A1 7-AZAINDOLE DERIVATIVES MERCK PATENT GMBH (DE) 2013-11-21 US disclosed
WO-2008064255-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130310391-A1 7-AZAINDOLE DERIVATIVES PDK1, PDK2, PDK3 DYRK1A 1000/4885ELANE 4375/4885CCNT1 25/4885
US-20230190751-A1 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors LATS1, LATS2, LSS DYRK1A 955/4885ELANE 4755/4885CCNT1 724/4885
US-20150152104-A1 7-AZAINDOLE DERIVATIVES PDK1, PDK2, PDK3 DYRK1A 1000/4885ELANE 4375/4885CCNT1 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.